OrbusNeich Medical Group Holdings Limited Fundamental Analysis
OrbusNeich Medical Group Holdings Limited Fundamental Analysis
OrbusNeich Medical Group Holdings Limited (6929.HK) shows moderate financial fundamentals with a PE ratio of 10.86, profit margin of 23.22%, and ROE of 10.20%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 68.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 6929.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak6929.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate6929.HK shows balanced valuation metrics.
Growth Score
Moderate6929.HK shows steady but slowing expansion.
Financial Health Score
Excellent6929.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate6929.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 6929.HK Expensive or Cheap?
P/E Ratio
6929.HK trades at 10.86 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 6929.HK's PEG of 15.77 indicates potential overvaluation.
Price to Book
The market values OrbusNeich Medical Group Holdings Limited at 1.10 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 15.78 times EBITDA. This signals the market has high growth expectations.
How Well Does 6929.HK Make Money?
Net Profit Margin
For every $100 in sales, OrbusNeich Medical Group Holdings Limited keeps $23.22 as profit after all expenses.
Operating Margin
Core operations generate 22.02 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.20 in profit for every $100 of shareholder equity.
ROA
OrbusNeich Medical Group Holdings Limited generates $9.25 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
OrbusNeich Medical Group Holdings Limited produces operating cash flow of $21.23M, showing steady but balanced cash generation.
Free Cash Flow
OrbusNeich Medical Group Holdings Limited produces free cash flow of $11.89M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.01 in free cash annually.
FCF Yield
6929.HK converts 2.63% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
10.86
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
15.77
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.10
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.51
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.009
vs 25 benchmark
Current Ratio
Current assets to current liabilities
10.54
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How 6929.HK Stacks Against Its Sector Peers
| Metric | 6929.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 10.86 | 29.01 | Better (Cheaper) |
| ROE | 10.20% | 730.00% | Weak |
| Net Margin | 23.22% | -53564.00% (disorted) | Strong |
| Debt/Equity | 0.01 | 0.39 | Strong (Low Leverage) |
| Current Ratio | 10.54 | 4.47 | Strong Liquidity |
| ROA | 9.25% | -18932.00% (disorted) | Weak |
6929.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews OrbusNeich Medical Group Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation